Quick Answer
Oncotelic Therapeutics, Inc. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2023.
Oncotelic Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$0.02 | -300.0% |
| 2022 | $0.01 | +133.3% |
| 2021 | -$0.03 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $0.00 | — | — |
| March 31, 2025 | $0.00 | — | +100.0% |
| September 30, 2024 | -$0.01 | — | — |
| June 30, 2024 | $0.00 | — | — |
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
| March 31, 2023 | $0.00 | — | — |
| September 30, 2022 | $0.00 | — | -100.0% |
- Oncotelic Therapeutics, Inc. showed a decrease of -300.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2023 period, Oncotelic Therapeutics, Inc.’s diluted eps has grown by 33.3% (from $0.03 per share (loss) to $0.02 per share (loss)).
- The most recent figure is from Oncotelic Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 12, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: